

XVI Congreso Chileno de Hematología
La Serena, Septiembre, 2008

**A NOVEL FAMILY OF MITOCHONDRIAL RNAs:
TARGET FOR DIAGNOSTIC AND THERAPY
OF CANCER.**

Luis O. Burzio

**ANDES
BioSciences SA**

FCPV
FUNDACION
CIENCIA PARA LA
VIDA



Grupo Bios SA

STRUCTURES OF THE HUMAN NON-CODING MITOCHONDRIAL RNAs (ncmtRNAs).

SENSE ncmtRNA:

loop 40 nts




ANTISENSE ncmtRNA:

loop 29 nts



loop 96 nts



loop 450 nts



— SENSE 16S Mitochondrial RNA
— ANTISENSE 16S Mitochondrial RNA

EXPRESSION OF THE SENSE AND ANTISENSE ncmtRNAs

SncmtRNA:

loop 40 nts



ASncmtRNA:


loop 29 nts




loop 96 nts




loop 450 nts



EXPRESSION OF THE SncmtRNA AND THE ASncmtRNAs IN NORMAL PROLIFERATING CELLS



EXPRESSION OF THE SncmtRNA AND THE ASncmtRNAs IN NORMAL PROLIFERATING TISSUES




	H&E	PCNA	SncmtRNA	ASncmtRNA
Brain				
Smooth muscle				
Liver				



ESPRESSION OF THE SncmtRNA AND THE ASncmtRNA IN DIFFERENT NORMAL PROLIFERATING TISSUES.

Tissue	No Cases	SncmtRNA	ASncmtRNAs
Normal skin	14	Positive	Positive
Cervical epithelium	22	Positive	Positive
Sebaceous gland	9	Positive	Positive
Esophagus epithelium	4	Positive	Positive
Kidney	6	Positive	Positive
Breast	8	Positive	Positive
Pancreas	5	Positive	Positive
Spleen	6	Positive	Positive
TOTAL	74		


THE EXPRESSION OF THE SncmtRNA AND ASncmtRNAs CAN BE INDUCED IN NON-DIVIDING HUMAN LYMPHOCYTES.



EXPRESSION OF THE SncmtRNA AND THE ASncmtRNAs IN TUMOR CELL LINES




EXPRESSION OF THE SncmtRNA AND THE ASncmtRNAs IN TUMORS



H&E SncmtRNA ASncmtRNA


Thyroid carcinoma




Bladder carcinoma




Glioblastoma multiforme




Lymphoma



Melanoma




Ovary carcinoma





NORMAL
SKIN

H & E




SncmtRNA

ASncmRNAs




MELANOMA


H & E



SncmtRNA




ASncmRNAs




ESPRESSION OF THE SncmtRNA AND THE ASncmtRNA IN DIFFERENT TYPES OF CANCER.

Tissue	No Cases	SncmtRNA	ASncmtRNAs
Breast carcinoma	64	Positive	Negative
Prostate carcinoma	27	Positive	Negative
Lung Carcinoma	14	Positive	Negative
Colon	17	Positive	Negative
Gallbladder	11	Positive	Negative
Stomach carcinoma	22	Positive	Negative
Uterine Cervix*	27	Positive	Negative
Brain tumors**	12	Positive	Negative
Kidney carcinoma	9	Positive	Negative
Hepatocarcinoma	5	Positive	Negative
Thyroid carcinoma	12	Positive	Negative
Ovary	8	Positive	Negative
Bladder	12	Positive	Negative
Melanomas	12	Positive	Negative
Lymphoma	6	Positive	Negative
Small intestine	3	Positive	Negative
Carcinoma			
TOTAL	261		


SUMMARY ON THE EXPRESSION OF THE ncmtRNAs IN HUMAN CELLS.



IMMORTALIZATION OF HUMAN KERATINOCYTES WITH PAPPILOMA VIRUS 16 OR 18



KERATINOCYTES IMMORTALIZED WITH HPV 16 or 18 INDUCE
DOWN REGULATE
THE ASncmtRNAs.




CONCLUSIONS:


- 1. THE SncmtRNA IS AN IMPORTANT FACTOR FOR CELL PROLIFERATION**
- 2. THE ASncmtRNA IS DOWN-REGULATES IN CANCER CELLS**
- 3. HYPOTHETICALY, THE ASncmtRNAs ARE NOVEL TUMOR SUPPRESSORS MITOCHONDRIALLY-ENCODED**

HOW TO STUDY THE FUNCTION OF THESE TRANSCRIPTS? KNOCK-DOWN OF THE RNAs


ASO or ANTISENSE
OLIGONUCLEOTIDES




NO SYNTHESIS OF PROTEIN



siRNAs or SMALL INTERFERING
RNAs




NO SYNTHESIS OF PROTEIN




PHYSIOLOGICAL CHANGES OF THE CELL

SUMMARY ON THE EXPRESSION OF THE ncmtRNAs IN HUMAN CELLS.





THE ASncmtRNAs AS TARGET FOR CANCER THERAPY





TWO MAIN QUESTIONS

- 1. WHICH TYPE OF CELL DEATH?**
- 2. KNOCK-DOWN OF MITOCHONDRIAL
TRANSCRIPTS???**


a) Testis SncmtRNA




b) Testis SncmtRNA



a) Testis ASncmtRNA



b) Testis ASncmtRNA



PROGRAMED CELL DEATH OR PCD

PCD TYPE 1 OR APOPTOSIS

- Translocation of phosphatidylserine
- Caspase activation
- DNA fragmentation
- Nuclear Fragmentation

PCD TYPE 2 OR AUTOPHAGY




- Autophagic vacuoles (AV) formation
- Fusion of AV with lysosomes (Autophagolysomes)
- Processing of LC3

TRANSLOCATION OF PHOSPHATIDYL SERINE

PHASE

ANEXIN V

Propidium I






ASO FOR THE ASncmtRNAs 0.1 uM for 18 H

PHASE

ANEXIN V

Propidium I




Staurosporin 4uM FOR 18 H

DNA FRAGMENTATION = TUNEL ASSAY


Control ASO



ASO x SncmtRNA



ASO x ASncmtRNA



CASPASE ACTIVATION = BINDING OF z-VADfmK-FITC


Control ASO







ASO x ASncmtRNA



STAUROSPORIN




NUCLEAR FRAGMENTATION & CHROMATIN CONDENZATION




INHIBITION OF CASPASES & CELL DEATH


Staurosporin 20uM




Staurosp. 20uM plus Z.VAD.fmk 50uM



ASO 0.1uM 18h




ASO 0.1uM plus Z.VAD.fmk 50uM




**DOES KNOCK-DOWN OF THE ASncmtRNAs ALSO INDUCE
PCD TYPE 2 OR AUTOPHAGY?**

CONTROL ASO



ASO 1537



ASO 1537

